Calliditas
Pharmaceutical company developing high value products for patients with significant unmet medical needs.
Launch date
Employees
Market cap
€982m
Enterprise valuation
€1.0b (Public information from Sep 2024)
Share price
$40.16 CALT
Company register number 556659-9766
Stockholms kommun Stockholm County (HQ)
Financials
Estimates*
| SEK | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | 229m | 803m | 1.2b | 2.0b | 3.4b | 4.9b |
| % growth | (100 %) | 26141 % | 250 % | 50 % | 64 % | 71 % | 44 % |
| EBITDA | (379m) | (524m) | (349m) | (373m) | 144m | 1.5b | 2.9b |
| % EBITDA margin | (43347 %) | (229 %) | (43 %) | (31 %) | 7 % | 44 % | 59 % |
| Profit | (433m) | (500m) | (412m) | (466m) | (183m) | 1.0b | 1.8b |
| % profit margin | (49599 %) | (218 %) | (51 %) | (39 %) | (9 %) | 30 % | 36 % |
| EV / revenue | 6837.5x | 22.5x | 6.2x | 5.7x | 5.7x | 2.8x | 1.4x |
| EV / EBITDA | -15.8x | -9.8x | -14.3x | -18.3x | 78.6x | 6.4x | 2.4x |
| R&D budget | 241m | 357m | 415m | 502m | - | - | - |
| R&D % of revenue | 27617 % | 156 % | 52 % | 42 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $1.0m | Seed | |
SEK35.0m | Early VC | ||
SEK96.0m | Series C | ||
| N/A | $12.0m | Early VC | |
* | N/A | $75.0m Valuation: $147m 1.8x EV/LTM Revenues -14.8x EV/LTM EBITDA | IPO |
| N/A | N/A | IPO | |
$75.0m | Post IPO Debt | ||
| N/A | SEK324m | Post IPO Equity | |
* | €92.0m | Post IPO Debt | |
* | SEK11.8b Valuation: SEK11.8b 9.8x EV/LTM Revenues -31.6x EV/LTM EBITDA | Acquisition | |
| Total Funding | €26.2m | ||
